B3GALT5

Summary

B3GALT5 (beta-1,3-galactosyltransferase 5, HGNC:920) is a protein-coding gene on chromosome 21q22.2, encoding Beta-1,3-galactosyltransferase 5 (Q9Y2C3). Catalyzes the transfer of Gal to GlcNAc-based acceptors with a preference for the core3 O-linked glycan GlcNAc(beta1,3)GalNAc structure.

This gene encodes a member of a family of membrane-bound glycoproteins. The encoded protein may synthesize type 1 Lewis antigens, which are elevated in gastrointestinal and pancreatic cancers. Alternatively spliced transcript variants using multiple alternate promoters have been observed for this gene.

Source: NCBI Gene 10317 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 13 total — 2 pathogenic, 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001356336

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:920
Approved symbol	B3GALT5
Name	beta-1,3-galactosyltransferase 5
Location	21q22.2
Locus type	gene with protein product
Status	Approved
Aliases	beta3Gal-T5, B3GalT-V, GLCT5, B3T5
Ensembl gene	ENSG00000183778
Ensembl biotype	protein_coding
OMIM	604066
Entrez	10317

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 25 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000343118, ENST00000380618, ENST00000380620, ENST00000398714, ENST00000475838, ENST00000615480, ENST00000682542, ENST00000682818, ENST00000683344, ENST00000684187, ENST00000684495, ENST00000852636, ENST00000852637, ENST00000852638, ENST00000852639, ENST00000852640, ENST00000852641, ENST00000852642, ENST00000852643, ENST00000852644, ENST00000852645, ENST00000852646, ENST00000852647, ENST00000852648, ENST00000852649, ENST00000852650, ENST00000941716

RefSeq mRNA: 8 — MANE Select: NM_001356336 NM_001278650, NM_001356336, NM_001356338, NM_001356339, NM_006057, NM_033170, NM_033171, NM_033172

CCDS: CCDS13667

Canonical transcript exons

ENST00000684187 — 4 exons

Exon	Start	End
ENSE00001485655	39659753	39659912
ENSE00001485657	39646392	39646622
ENSE00003704093	39660560	39673137
ENSE00003719844	39612940	39613067

Expression profiles

Bgee: expression breadth ubiquitous, 146 present calls, max score 96.28.

FANTOM5 (CAGE): breadth broad, TPM avg 1.3102 / max 169.8261, expressed in 359 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
189179	0.7044	250
189178	0.2296	111
189185	0.1848	28
189180	0.0695	38
189181	0.0630	33
189184	0.0589	4

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	96.28	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.20	gold quality
jejunal mucosa	UBERON:0000399	92.91	gold quality
colonic mucosa	UBERON:0000317	92.63	gold quality
rectum	UBERON:0001052	92.30	gold quality
duodenum	UBERON:0002114	88.12	gold quality
mucosa of transverse colon	UBERON:0004991	85.42	gold quality
amniotic fluid	UBERON:0000173	85.08	gold quality
sperm	CL:0000019	83.19	silver quality
male germ cell	CL:0000015	80.40	silver quality
jejunum	UBERON:0002115	80.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.76	gold quality
ileal mucosa	UBERON:0000331	78.88	silver quality
small intestine	UBERON:0002108	78.39	gold quality
epithelium of nasopharynx	UBERON:0001951	77.99	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.74	gold quality
small intestine Peyer’s patch	UBERON:0003454	77.66	gold quality
mammary duct	UBERON:0001765	77.08	silver quality
oral cavity	UBERON:0000167	75.36	gold quality
transverse colon	UBERON:0001157	75.32	gold quality
epithelium of mammary gland	UBERON:0003244	74.82	silver quality
nasal cavity epithelium	UBERON:0005384	74.75	silver quality
islet of Langerhans	UBERON:0000006	74.62	gold quality
lower esophagus mucosa	UBERON:0035834	74.53	gold quality
mucosa of paranasal sinus	UBERON:0005030	74.31	silver quality
gall bladder	UBERON:0002110	73.94	gold quality
intestine	UBERON:0000160	72.35	gold quality
pancreatic ductal cell	CL:0002079	71.86	silver quality
nasal cavity mucosa	UBERON:0001826	70.49	gold quality
large intestine	UBERON:0000059	70.39	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	22.95
E-ANND-3	yes	6.54

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CDX1, CDX2, HNF1A, HNF1B

miRNA regulators (miRDB)

83 targeting B3GALT5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489

Literature-anchored findings (GeneRIF, showing 16)

• case study of the endogenous retrovirus long terminal repeat promoter of this enzyme (PMID:16112824)
• the enhanced expression of beta 3GalT5 is sufficient to promote in vivo extension of type 1 chains by furnishing a significantly higher amount of type 1 chain precursors relative to competing type 2 chains. (PMID:19136585)
• We found beta3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer (PMID:19225246)
• The B3GALT5 promoter is activated by serum depletion according to promoter reporter assays in HEK 293 cells. (PMID:20494980)
• Chromatin immunoprecipitation assays on beta3Gal-T5 promoter showed that histone H3K4 trymethylation, H3K79 dimethylation, and H3K9-14 acetylation are high in cells expressing the transcript. (PMID:22001559)
• Data conclude that HNF1alpha/beta are necessary but insufficient to activate and regulate B3GALT5 LTR transcription, which depends on unknown regulatory elements that are active when methylated and located outside of and far from the LTR promoter. (PMID:24128890)
• CA19.9 appears as a physiological product whose synthesis strongly depends on the tissue specific and epigenetically-regulated expression of B3GALT5 and ST3GAL3. (PMID:27535614)
• In patients with hepatocellular carcinoma, Kaplan Meier survival analysis showed significantly shorter relapse-free survival for those with high expression of B3GALT5 and shorter overall survival. (PMID:28883415)
• Here we show that the expression of beta3GalT5 significantly correlates with tumor progression and poor survival in patients, and the globo-series GSLs in breast cancer cells form a complex in membrane lipid raft with caveolin-1 (CAV1) and focal adhesion kinase (FAK) which then interact with AKT and receptor-interacting protein kinase (RIP), respectively (PMID:30808745)
• SSEA3 and Sialyl Lewis a Glycan Expression Is Controlled by B3GALT5 LTR through Lamin A-NFYA and SIRT1-STAT3 Signaling in Human ES Cells. (PMID:31936807)
• Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer. (PMID:32207329)
• B3GALT5 knockout alters gycosphingolipid profile and facilitates transition to human naive pluripotency. (PMID:33087559)
• High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer. (PMID:33413566)
• B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis. (PMID:36495345)
• High expression of B3GALT5 suppresses the galectin-4-mediated peritoneal dissemination of poorly differentiated gastric cancer cells. (PMID:39163480)
• Highly expressed B3GALT5-AS1 contributes to gastric cancer progression by recruiting WDR5 to mediate B3GALT5 and regulating beta-catenin/ZEB1 axis. (PMID:39224045)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	b3galt10.1	ENSDARG00000061432
danio_rerio	b3galt10.2	ENSDARG00000061496
danio_rerio	b3galt8	ENSDARG00000097795
danio_rerio		ENSDARG00000109569
mus_musculus	B3galt5	ENSMUSG00000074892
rattus_norvegicus	B3galt5	ENSRNOG00000030983
drosophila_melanogaster	brn	FBGN0000221
caenorhabditis_elegans		WBGENE00000270
caenorhabditis_elegans		WBGENE00007096
caenorhabditis_elegans		WBGENE00017653

Paralogs (15): B3GNT7 (ENSG00000156966), B3GALT2 (ENSG00000162630), B3GALNT2 (ENSG00000162885), B3GALNT1 (ENSG00000169255), B3GNT2 (ENSG00000170340), B3GALT1 (ENSG00000172318), B3GALT6 (ENSG00000176022), B3GNT4 (ENSG00000176383), B3GNT5 (ENSG00000176597), B3GNT8 (ENSG00000177191), B3GNT3 (ENSG00000179913), B3GNT6 (ENSG00000198488), B3GALT9 (ENSG00000214654), B3GALT4 (ENSG00000235863), B3GNT9 (ENSG00000237172)

Protein

Protein identifiers

Beta-1,3-galactosyltransferase 5 — Q9Y2C3 (reviewed: Q9Y2C3)

Alternative names: Beta-3-Gx-T5, UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 5, UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase 5

All UniProt accessions (2): A0A0A0MS93, Q9Y2C3

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the transfer of Gal to GlcNAc-based acceptors with a preference for the core3 O-linked glycan GlcNAc(beta1,3)GalNAc structure. Can use glycolipid LC3Cer as an efficient acceptor.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Expressed in stomach, jejunum, colon, pancreas, small intestine, testis and gastrointestinal and pancreatic cancer cell lines. Hardly detected in lung, liver, adrenal gland and peripheral blood leukocytes.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 31 family.

RefSeq proteins (8): NP_001265579, NP_001343265, NP_001343267, NP_001343268, NP_006048, NP_149360, NP_149361, NP_149362 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002659	Glyco_trans_31	Family

Pfam: PF01762

Catalyzed reactions (Rhea), 1 shown:

• a globoside Gb4Cer (d18:1(4E)) + UDP-alpha-D-galactose = a globoside GalGb4Cer (d18:1(4E)) + UDP + H(+) (RHEA:41996)

UniProt features (13 total): sequence conflict 3, glycosylation site 3, sequence variant 3, topological domain 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
8ZWP	X-RAY DIFFRACTION	1.86
8ZWW	X-RAY DIFFRACTION	1.87
8ZWR	X-RAY DIFFRACTION	1.94
8ZWY	X-RAY DIFFRACTION	1.95
8ZX3	X-RAY DIFFRACTION	2.09
8ZX9	X-RAY DIFFRACTION	2.3
8ZX2	X-RAY DIFFRACTION	2.4
8ZX8	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2C3-F1	92.69	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 130, 174, 231

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9037629	Lewis blood group biosynthesis
R-HSA-1430728	Metabolism
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives
R-HSA-9033658	Blood group systems biosynthesis

MSigDB gene sets: 121 (showing top): BROWNE_HCMV_INFECTION_4HR_UP, GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, BROWNE_HCMV_INFECTION_16HR_UP, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GLOBO_SERIES, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, MODULE_99, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_BIOSYNTHETIC_PROCESS, SABATES_COLORECTAL_ADENOMA_DN, chr21q22, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, REACTOME_METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES

GO Biological Process (7): protein O-linked glycosylation (GO:0006493), lipid metabolic process (GO:0006629), glycoprotein biosynthetic process (GO:0009101), oligosaccharide biosynthetic process (GO:0009312), response to bacterium (GO:0009617), obsolete protein glycosylation (GO:0006486), carbohydrate derivative biosynthetic process (GO:1901137)

GO Molecular Function (5): N-acetyl-beta-D-glucosaminide beta-(1,3)-galactosyltransferase activity (GO:0008499), protein binding (GO:0005515), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), hexosyltransferase activity (GO:0016758)

GO Cellular Component (4): Golgi membrane (GO:0000139), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Blood group systems biosynthesis	1
Metabolism	1
Metabolism of carbohydrates and carbohydrate derivatives	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
glycoprotein biosynthetic process	1
primary metabolic process	1
macromolecule biosynthetic process	1
glycoprotein metabolic process	1
carbohydrate derivative biosynthetic process	1
oligosaccharide metabolic process	1
carbohydrate biosynthetic process	1
response to other organism	1
biosynthetic process	1
carbohydrate derivative metabolic process	1
UDP-galactosyltransferase activity	1
beta-1,3-galactosyltransferase activity	1
binding	1
catalytic activity	1
transferase activity	1
glycosyltransferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

738 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
B3GALT5	C1GALT1	Q9NS00	944
B3GALT5	FUT1	P19526	633
B3GALT5	FUT2	Q10981	583
B3GALT5	ST6GALNAC6	Q969X2	551
B3GALT5	B4GALT4	O60513	545
B3GALT5	FUT3	P21217	537
B3GALT5	GCNT3	O95395	534
B3GALT5	LCA5L	O95447	529
B3GALT5	A4GALT	Q9NPC4	522
B3GALT5	ST3GAL5	Q9UNP4	518
B3GALT5	B4GALT1	P15291	511
B3GALT5	B4GALNT2	Q8NHY0	507
B3GALT5	PSMG1	O95456	507
B3GALT5	ST3GAL2	Q16842	495
B3GALT5	FUT9	Q9Y231	491

IntAct

8 interactions, top by confidence:

A	B	Type	Score
CLEC2D	B3GALT5	psi-mi:“MI:0915”(physical association)	0.560
DEFB103A	B3GALT5	psi-mi:“MI:0915”(physical association)	0.560
OR6N1	B3GALT5	psi-mi:“MI:0915”(physical association)	0.400
B3GALT5	TTI1	psi-mi:“MI:0914”(association)	0.350
B3GALT5	CLEC2D	psi-mi:“MI:0915”(physical association)	0.000
B3GALT5	DEFB103A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): B3GALT5 (Two-hybrid), B3GALT5 (Two-hybrid), B3GALT5 (Two-hybrid), SLC30A6 (Affinity Capture-MS), SLC30A1 (Affinity Capture-MS), BDH1 (Affinity Capture-MS), RMND1 (Affinity Capture-MS), FAIM (Affinity Capture-MS), CANX (Affinity Capture-MS), P2RX4 (Affinity Capture-MS), PODXL2 (Affinity Capture-MS), GAL (Affinity Capture-MS), CSGALNACT2 (Affinity Capture-MS), TTI1 (Affinity Capture-MS), FAM3C (Affinity Capture-MS)

ESM2 similar proteins: A0A2C9JXL4, O43825, O54904, O54905, O75752, O93403, P79948, P79949, Q08BL3, Q0VC84, Q24342, Q5F3G7, Q5HZL5, Q5R5Y3, Q5RAL7, Q5XJP0, Q5YB40, Q66H69, Q6AY39, Q6DE15, Q6GNL1, Q6P3P5, Q6QMG1, Q76EC5, Q793U7, Q7JK24, Q7JK25, Q7JK26, Q7K237, Q7SYI5, Q7T3S5, Q864U6, Q864U8, Q8BGY6, Q8K0J2, Q8NFL0, Q920V1, Q99NB2, Q9BYG0, Q9JI67

Diamond homologs: A8MXE2, O43825, O54904, O54905, O75752, O88178, O96024, Q1RLK6, Q5HZL5, Q5JCS9, Q5R5Y3, Q5RAL7, Q66H69, Q6AY39, Q6DE15, Q6P3P5, Q793U7, Q7JK24, Q7JK25, Q7JK26, Q7T3S5, Q864U6, Q864U8, Q8BGY6, Q8R3I9, Q920V1, Q95US5, Q99NB2, Q9BYG0, Q9C0J1, Q9JI67, Q9MYM7, Q9N293, Q9N294, Q9N295, Q9Y2A9, Q9Y2C3, Q9Y5Z6, Q9Z0F0, Q3USF0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

13 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	8
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
146086	GRCh38/hg38 21q22.12-22.2(chr21:35543872-39993338)x1	Pathogenic
395335	GRCh37/hg19 21q22.13-22.2(chr21:38176362-41901945)x1	Pathogenic
443777	GRCh37/hg19 21q22.12-22.2(chr21:36183329-42311538)x3	Likely pathogenic

SpliceAI

1583 predictions. Top by Δscore:

Variant	Effect	Δscore
21:39556511:G:GG	donor_gain	1.0000
21:39605223:GCA:G	donor_gain	1.0000
21:39605226:G:GG	donor_gain	1.0000
21:39556508:AAT:A	donor_gain	0.9900
21:39556508:AATG:A	donor_loss	0.9900
21:39556510:TGTG:T	donor_loss	0.9900
21:39556512:T:A	donor_loss	0.9900
21:39558274:T:A	acceptor_gain	0.9900
21:39578848:GGAA:G	donor_gain	0.9900
21:39605088:TTGCA:T	acceptor_loss	0.9900
21:39605089:TGCA:T	acceptor_loss	0.9900
21:39605090:GCA:G	acceptor_loss	0.9900
21:39605091:CA:C	acceptor_loss	0.9900
21:39605092:A:AT	acceptor_loss	0.9900
21:39605194:C:T	donor_gain	0.9900
21:39605221:CCGCA:C	donor_gain	0.9900
21:39659751:A:AG	acceptor_gain	0.9900
21:39659751:AGT:A	acceptor_gain	0.9900
21:39659752:G:GG	acceptor_gain	0.9900
21:39659752:GT:G	acceptor_gain	0.9900
21:39659752:GTG:G	acceptor_gain	0.9900
21:39659913:G:GG	donor_gain	0.9900
21:39661527:A:G	donor_gain	0.9900
21:39556507:AAAT:A	donor_gain	0.9800
21:39556509:AT:A	donor_gain	0.9800
21:39556513:GAG:G	donor_loss	0.9800
21:39578838:AACCT:A	donor_gain	0.9800
21:39578843:G:GG	donor_gain	0.9800
21:39605092:A:AG	acceptor_gain	0.9800
21:39605093:G:GG	acceptor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000052312 (21:39637787 T>G), RS1000112770 (21:39636533 A>G), RS1000126124 (21:39656088 C>G,T), RS1000174079 (21:39618156 TA>T), RS1000294625 (21:39653332 A>G), RS1000305088 (21:39614173 G>A,T), RS1000337364 (21:39620500 T>C,G), RS1000358514 (21:39664418 C>T), RS1000367199 (21:39620713 A>G,T), RS1000369340 (21:39670201 C>T), RS1000401297 (21:39662278 C>A), RS1000511691 (21:39649760 G>T), RS1000520135 (21:39669792 C>G,T), RS1000572652 (21:39627830 T>A,C), RS1000609830 (21:39656321 T>C)

Disease associations

OMIM: gene MIM:604066 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000854_1	Suicide risk	6.000000e-06
GCST003121_8	Alcohol dependence	5.000000e-06
GCST003434_2	Obsessive-compulsive symptoms	4.000000e-07
GCST005803_16	Corneal astigmatism	9.000000e-06
GCST009391_1597	Metabolite levels	8.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004321	attempted suicide
EFO:0007802	obsessive-compulsive symptom measurement
EFO:1002040	Corneal astigmatism
EFO:0010376	phosphatidylcholine 34:2 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2321635 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects methylation, increases expression	3
kaempferol	decreases expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Zoledronic Acid	decreases expression	1
Arsenic	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	increases expression	1
Estradiol	affects cotreatment, increases expression	1
Chlordecone	decreases expression	1
Methapyrilene	increases methylation	1
Phthalic Acids	increases methylation	1
Tamoxifen	decreases expression	1
Dronabinol	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1
Copper Sulfate	decreases expression	1
Apigenin	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2329442	Binding	Inhibition of human recombinant soluble His-tagged beta3-GalT5 expressed in insect cells using GlcNAcbeta-Bn as substrate at 0.5 mM after 1 hr relative to control	Selective inhibition of glycosyltransferases by bivalent imidazolium salts. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.